Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miramax
- Development stage
- Unknown
- Lead developer
- Lyceum
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Miramax is a branded generic nutraceutical combination formulation containing Ginkgo biloba (120 mg) and L-carnitine (500 mg). Developed by Lyceum Life Sciences, it is marketed as a dietary supplement to support cognitive wellbeing, enhance memory, focus, and mental alertness, and improve blood circulation and cellular energy metabolism.
- Brand names
- Miramax
- Other names
- Ginkgo Biloba + L-Carnitine
02
Targets
CRAT (Carnitine O-acetyltransferase)SLC7A1 (Cationic amino acid transporter 1)MAOA (Monoamine oxidase A)MAOB (Monoamine oxidase B)PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on Miramax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Miramax.